摘要
目的观察重组人脑利钠肽(rh BNP)治疗硝普钠疗效欠佳扩张型心肌病慢性心力衰竭急性加重的临床效果。方法 20例扩张型心肌病慢性心力衰竭急性加重硝普钠治疗效果欠佳的患者为研究对象,观察重组人脑利钠肽治疗前后患者临床症状、体征及心功能改善情况,对临床效果进行评价。结果治疗后,心率(HR)、脑利钠肽(BNP)较治疗前明显降低,差异有统计学意义(P<0.001);左室射血分数(LVEF)、左室舒张末期内径(LVEDd)均较治疗前有明显改善,差异有统计学意义(P<0.001)。结论重组人脑利钠肽对于治疗硝普钠疗效欠佳扩张型心肌病慢性心力衰竭急性加重具有较好的临床作用且不良反应少,可在临床推广应用。
Objective To observe clinical effect of recombinant human brain natriuretic peptide （rhBNP） for dilated cardiomyopathy chronic heart failure acute exacerbation patients with poor effect by sodium nitroprusside. Methods There were 20 dilated cardiomyopathy chronic heart failure acute exacerbation patients with poor effect by sodium nitroprusside as study subjects. Their improvements in clinical symptoms, signs, and cardiac function were observed before and after recombinant human brain natriuretic peptide treatment. Their clinical effects were evaluated. Results After treatment, heart rate （HR） and brain natriuretic peptide （BNP） were much lower than those before treatment, and their difference had statistical significance （P〈O.001）. Left ventricular ejection fraction （LVEF） and left ventricular end-diastolic dimension （LVEDd） were all improved after treatment, and their difference had statistical significance （P〈0.001）. Conclusion Recombinant human brain natriuretic peptide privodes precisely clinical effect for dilated cardiomyopathy chronic heart failure acute exacerbation patients with poor effect by sodium nitroprusside, with few adverse reactions. This method is worth clinical promotion and application.
出处
《中国实用医药》
2015年第28期1-3,共3页
China Practical Medicine
关键词
重组人脑利钠肽
硝普钠
扩张型心肌病
心力衰竭
Recombinant human brain natriuretic peptide
Sodium nitroprusside
Dilated cardiomyopathy
Heart failure
